CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
42 hedge funds and large institutions have $58.4M invested in CTI BioPharma Corp. (DE) Common Stock in 2017 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 7 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
5% more funds holding
Funds holding: 40 → 42 (+2)
4% less capital invested
Capital invested by funds: $61M → $58.4M (-$2.54M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.78M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.08M |
| 3 |
Renaissance Technologies
New York
|
+$916K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$684K |
| 5 |
JP Morgan Chase
New York
|
+$285K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.31M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.54M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$837K |
| 4 |
TA
Tiedemann Advisors
New York
|
-$242K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
-$169K |
CTIC Hedge Fund Activity: Q3 2017 in Review
42 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2017, worth a combined $58.4M — down 4.2% from $61M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CTIC positions and 7 closed out — a net gain of 3 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $2.78M. The largest seller was Stonepine Capital Management, cutting an estimated $4.31M.
- 42 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2017, up from 40 in Q2 2017.
- Funds reported $58.4M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2017, down 4.2% quarter-over-quarter.
- 10 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2017 and 7 closed out, a net change of +3 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2017 was Sphera Funds Management, an estimated $2.78M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2017 was Stonepine Capital Management, an estimated $4.31M sold.
Based on aggregated 13F filings for Q3 2017.